THY1 and ovarian carcinoma: To determine the effect of HATMSC2 -MVs on the phenotype of ovarian cancer cell lines treated at the ratios of 10:1 and 100:1, we tested the presence of the CD34, CD44, CD133, SSEA4, CD73, CD90, and CD105 markers using flow cytometry.